Author:
Schrieber Sarah J.,Putnam Wendy S.,Chow Edwin Chiu Yuen,Cieslak Jacek,Zhuang Yanli,Martin Steven W.,Hanson Paul,Maggio Frank,Rosado Leslie A. Rivera
Publisher
Springer Science and Business Media LLC
Reference9 articles.
1. US Food and Drug Administration. IND Activity. https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/ind-activity. Accessed Sept 2019.
2. Dye E, et al. Examining manufacturing readiness for breakthrough drug development. AAPS PharmSciTech. 2016;17:529–38.
3. Xu S, et al. Skin sensors are the future of health care. Nature. 2019;571:319–21.
4. Proposed regulatory framework for modifications to artificial intelligence/machine learning (AI/ML)-based software as a medical device (SaMD). April 2, 2019. https://www.regulations.gov/document?D=FDA-2019-N-1185-0001. Accessed Sept 2019.
5. Zhuang Y, et al. Risk-based comparability assessment for monoclonal antibodies during drug development: a clinical pharmacology perspective. AAPS J. 2018;20:109.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献